In recent years, new guidelines have been released that help patients and health care providers in treating psoriasis and psoriatic arthritis.
In November 2018, the National Psoriasis Foundation and the American College of Rheumatology collaborated to release a joint treatment guideline for psoriatic arthritis (PsA).
The NPF and the American Academy of Dermatologists also worked together to release updated psoriasis guidelines, which are being published in sections beginning in 2019 and ending in 2020. These cover a range of topics from biologic therapies to treating pediatric patients.
We’re lucky to have this guidance, but it does mean a large amount of information to digest and then translate into practical use. That’s why we’ve gathered these guidelines in one place.
The guideline provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for patients with active PsA who have not been treated and patients who continue to have active PsA despite treatment.
The new guidelines for the management and treatment of psoriasis represent the first update and augmentation of psoriasis treatment guidelines in a decade. These guidelines, published in sections, offer guidance on biologics, comorbidities, phototherapy, pediatric psoriasis, systemic non-biologic therapies and topicals. The last section, topicals, is expected to be published in Summer 2020.